Ramelteon

CNS Drugs

Volumn 19, Issue 12, 2005, Pages 1057-1065

  McGechan, Adam ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; DEXTROMETHORPHAN; DIAZEPAM; DIGOXIN; DOPAMINE; FLUOXETINE; FLUVOXAMINE; HORMONE RECEPTOR STIMULATING AGENT; KETOCONAZOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MIDAZOLAM; N ACETYLSEROTONIN; OMEPRAZOLE; OPIATE; RAMELTEON; RIFAMPICIN; SEROTONIN; SEROTONIN RECEPTOR; THEOPHYLLINE; UNCLASSIFIED DRUG; WARFARIN;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ARTHRALGIA; ARTICLE; BEHAVIOR; BINDING AFFINITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFLUENZA; INSOMNIA; MAMMAL; MYALGIA; NAUSEA; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SEDATION; SLEEP; SLEEP TIME; SOMNOLENCE; TREATMENT CONTRAINDICATION; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; BIOTRANSFORMATION; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; INDENES; RECEPTORS, MELATONIN; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TISSUE DISTRIBUTION;

EID: 28844473913     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519120-00007     Document Type: Article

References (33)

1. Winkelman J, Pies R. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry 2005 Jan 31; 17 (1): 31-40
2. Silber MH. Chronic insomnia. N Engl J Med 2005 Aug 25; 353 (8): 803-10
3. National Institutes of Health. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults: final statement [online]. Available from URL: http://consensus.nih.gov [Accessed 2005 Oct 28]
4. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60 (2): 413-45
5. Stiefel F, Stagno D. Management of insomnia in patients with chronic pain conditions. CNS Drugs 2004; 18 (5): 285-96
6. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim) 2005 Jun; 338 (5-6): 229-47
7. Brzezinski A. Melatonin in humans. N Engl J Med 1997 Jan 16; 336 (3): 186-95
8. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005; 20 (1): 27-37
9. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5 (6): 523-32
10. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48 (2): 301-10
11. Hirai K, Kato K, Nishiyama K, et al. TAK-375 and its metabolites are selective agonists at MLs1s receptors [abstract no. 0193.C]. Sleep 2003; 26 Abstr. Suppl.: A79
12. Miyamoto M, Kato K, Hirai K, et al. TAK-375 and its active metabolite: lack of binding to non-ML receptor bindings sites [abstract no. 0194.C]. Sleep 2003; 26 Abstr. Suppl.: A79
13. Yukuhiro N, Kimura H, Nishikawa H, et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004; 1027 (1-2): 59-66
14. Miyamoto M, Nishikawa H, Doken Y, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004; 27 (7): 1319-25
15. 1-selective melatonin receptor agonist, in experimental animals [abstract no. P.03.125]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S213
16. Erman M, Seiden D, Zammit G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia [abstract no. 0748.L]. Sleep 2003; 26 Abstr. Suppl.: A298
17. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28 (3): 303-7
18. Greenblatt DJ, Harmatz JS. Effect of age and gender on the pharmacodynamics of TAK-375: tests of sedation, psychomotor function, and memory [abstract no. 0197.C]. Sleep 2003; 26 Abstr. Suppl.: A80-1
19. Takeda Pharmaceuticals America Inc. Rozerem™ (ramelteon) tablets: prescribing information [online]. Available from URL: http://www.rozerem.com/pi. pdf [Accessed 2005 Oct 7]
20. FDA. Center for Drug Evaluation and Research. Application number 21-782: Ramelteon (TAK-375). Medical Review [online]. Available from URL: http://www.fda.gov [Accessed 2005 Nov 4]
21. Stevenson S, Bryson S, Amakye D, et al. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects [abstract no. PI-75]. Clin Pharmacol Ther 2004; 75 (2): P22
22. Stevenson S, Cornelissen K, Clarke E, et al. Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) [abstract no. PI-74]. Clin Pharmacol Ther 2004; 75 (2): P22
23. Stubbs C, Karim A. A safety, tolerance, and pharmacokinetic study of five single doses of TAK-375 in healthy adults [abstract no. 0187.C]. Sleep 2003; 26 Abstr. Suppl.: A76-7
24. Greenblatt DJ, Harmatz JS. Age and gender effects on the pharmacokinetics of TAK-375 [abstract no. 0198.C]. Sleep 2003; 26 Abstr. Suppl.: A81
25. Karim A, Tolbert D, Cao C, et al. Study to assess the steady-state drug-drug interaction of omeprazole with ramelteon in healthy adults [abstract no. 0137]. Sleep 2005; 28 Abstr. Suppl.: A46
26. Karim A, Tolbert D, Cao C. Effects of fluoxetine on the systemic exposure of ramelteon (TAK-375) [abstract no. NR844 plus poster]. 157th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2005 May 1-6; New York, 317
27. Roth T, Seiden D, Weigand S, et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [abstract no. II-87]. 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2005 Jun 6-9; Boca Raton (FL)
28. Zammit G, Roth T, Erman M, et al. Polysomnography and outpatient study to determine the efficacy of ramelteon in adults with chronic insomnia [abstract no. NR613 plus poster]. 158th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2005 May 21-26; Atlanta (GA), 227
29. Roth T, Seiden D, Zee P, et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients [abstract no. A21]. J Am Geriatr Soc 2005; 53 (4 Suppl.): S25
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington DC: American Psychiatric Association, 2000
31. Zammit G, Schwartz H, Roth T, et al. Phase III study of ramelteon in a first-night-effect model of transient insomnia [abstract no. O 007]. World Association of Sleep Medicine First Congress; 2005 Oct 15-18; Berlin
32. Seiden D, Zee P, Weigand S, et al. Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia in an elderly population [abstract no. 0679]. Sleep 2005; 28 Abstr. Suppl.: A228
33. Griffiths RR, Suess P. Ramelteon (TAK-375) and triazolam in humans: behavioral effects and abuse potential [abstract no. NR207 plus poster]. 158th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2005 May 21-26; Atlanta (GA), 76-7